ArticleThe Journal of clinical investigation2013
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Identification of immune-related targets of N6-methyladenosine regulators in hepatocellular carcinoma via RNA-seq analysis.Translational cancer research · 2026Article
- Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.NPJ vaccines · 2025Review
- Expression and clinical significance of NLRC5 in hepatocellular carcinoma.Cancer biology & therapy · 2024Article
- Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment.Pharmaceutics · 2023Article
- Establishment of image-guided radiotherapy of orthotopic hepatocellular carcinoma mouse model.Animal models and experimental medicine · 2023Article
- Advances in experimental animal models of hepatocellular carcinoma.Cancer medicine · 2023Review
- The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma.Journal of liver cancer · 2022Article
- Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy.World journal of gastrointestinal oncology · 2021Review
- Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.World journal of gastrointestinal oncology · 2021Review
- Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.Journal for immunotherapy of cancer · 2019Review
- Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.World journal of gastroenterology · 2019Review
- Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.Therapeutic advances in medical oncology · 2019Review
- Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion.Nature communications · 2018Article
- Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.Nature communications · 2017Article
- Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments.Cancer management and research · 2017Review
- Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.Journal of hepatology · 2017Article
- Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.The oncologist · 2016Article
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.Immunotherapy · 2016Review
- Immunological landscape and immunotherapy of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2015Review
- An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.Nature protocols · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell surveillance is often effective against virus-associated tumors because of their high immunogenicity. It is not clear why surveillance occasionally fails, particularly against hepatitis B virus- or hepatitis C virus-associated hepatocellular carcinoma (HCC). We established a transgenic murine model of virus-induced HCC by hepatocyte-specific adenovirus-induced activation of the oncogenic SV40 large T antigen (TAg). Adenovirus infection induced cytotoxic T lymphocytes (CTLs) targeted against the virus and TAg, leading to clearance of the infected cells. Despite the presence of functional, antigen-specific T cells, a few virus-infected cells escaped immune clearance and progressed to HCC. These cells expressed TAg at levels similar to HCC isolated from neonatal TAg-tolerant mice, suggesting that CTL clearance does not select for cells with low immunogenicity. Virus-infected mice revealed significantly greater T cell infiltration in early-stage HCC compared with that in late-stage HCC, demonstrating progressive local immune suppression through inefficient T cell infiltration. Programmed cell death protein-1 (PD-1) and its ligand PD-L1 were expressed in all TAg-specific CD8+ T cells and HCC, respectively, which contributed to local tumor-antigen-specific tolerance. Thus, we have developed a model of virus-induced HCC that may allow for a better understanding of human HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.